Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
Ability to serially monitor treatment response, identify key biomarkers and customize assay aids clinical research efforts to improve treatment for metastatic cancers involving brain and spinal cord
Excerpt from the Press Release:
SAN DIEGO–(BUSINESS WIRE)–Feb. 22, 2022– Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, highlighted the ability of its CNSide™ cerebrospinal fluid (CSF) assay to aid in therapeutic research programs for metastatic brain cancer in a presentation at the Molecular & Precision Med Tri-Con meeting. The company is also exhibiting (booth #508) at the conference, which is the leading international meeting for the precision medicine community, Feb. 21-23, 2022, in San Diego.
During the presentation, Michael Dugan, M.D., Biocept’s Chief Medical Officer and Medical Director, discussed the growing interest in improving the diagnosis and treatment of leptomeningeal disease (LMD), a devastating complication in which metastatic cancer spreads to the membrane surrounding the brain and spinal cord. Newer targeted therapies can often reduce or resolve debilitating symptoms of LMD and extend life expectancy. However, the current standards of care, CSF cytology and radiological imaging, have limited sensitivity for detecting central nervous system metastasis, and do not identify molecular treatment targets or quantify tumor cell counts.
“A key to precision medicine is identifying molecular targets for therapy,” Dr. Dugan said. “Relying on the primary tumor is not sufficient because biomarker status often differs between the primary and metastatic tumors. With CNSide, we have the first commercially available method to measure biomarker status in real-time during therapy and quantify changes in tumor cell counts to really understand how patients are responding to therapy—as opposed to waiting months for radiologic changes or another surgical biopsy.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?